Serina Therapeutics, Inc. (SER) Stock Price

SERStock

$2.70−53.45%52W

Market Cap$68.58M

P/E—

PEG Ratio—

Div yield—

Beta7.52

SER Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)45.30%

Price vs S&P 500 (4W)24.00%

VGM Score44.64

Book Value / Share (Quarterly)$1.18

Revenue Growth (3Y)63.03%

Cash Flow / Share (Quarterly)$-1.23

Price vs S&P 500 (YTD)25.52%

Gross Margin (TTM)65.07%

Net Profit Margin (TTM)-3498.61%

EPS (TTM)$-1.89

10-Day Avg Trading Volume0.08M

EPS Excl Extra (TTM)$-1.89

Revenue Growth (5Y)-18.43%

EPS (Annual)$-1.88

ROI (Annual)-1738.07%

Gross Margin (Annual)71.83%

Net Profit Margin (5Y Avg)-17228.27%

Cash / Share (Quarterly)$1.65

Revenue Growth QoQ (YoY)154.90%

ROA (Last FY)-275.96%

Revenue Growth TTM (YoY)3.17%

EBITD / Share (TTM)$-2.28

ROE (5Y Avg)-549.42%

Operating Margin (TTM)-7553.47%

Cash Flow / Share (Annual)$-1.67

P/B Ratio2.39x

P/B Ratio (Quarterly)1.36x

Net Income / Employee (Annual)$-1,198,900

EV / Revenue (TTM)143.24x

Net Interest Coverage (TTM)-89.13x

ROA (TTM)-219.00%

EPS Incl Extra (Annual)$-1.88

Current Ratio (Annual)1.71x

Quick Ratio (Quarterly)3.92x

3-Month Avg Trading Volume0.08M

52-Week Price Return-53.45%

Revenue / Employee (TTM)$8,100

P/S Ratio (Annual)324.18x

Asset Turnover (Annual)0.02x

52-Week High$7.92

Operating Margin (5Y Avg)-16851.61%

EPS Excl Extra (Annual)$-1.88

CapEx CAGR (5Y)24.16%

26-Week Price Return56.55%

Quick Ratio (Annual)0.94x

13-Week Price Return39.37%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)4.18x

Enterprise Value$20.63M

Revenue / Share Growth (5Y)5.92%

Asset Turnover (TTM)0.02x

Revenue / Employee (Annual)$8,100

Pretax Margin (Annual)-14766.92%

Cash / Share (Annual)$0.28

3-Month Return Std Dev79.56%

Gross Margin (5Y Avg)82.27%

Net Income / Employee (TTM)$-1,198,900

ROE (Last FY)-1738.07%

Net Interest Coverage (Annual)-66.49x

EPS Basic Excl Extra (Annual)$-1.88

Receivables Turnover (TTM)3.76x

Total Debt / Equity (Quarterly)0.17x

EPS Incl Extra (TTM)$-1.89

Receivables Turnover (Annual)4.98x

ROI (TTM)-583.22%

P/S Ratio (TTM)292.66x

Pretax Margin (5Y Avg)-17280.99%

Revenue / Share (Annual)$0.01

Price vs S&P 500 (52W)-71.76%

Year-to-Date Return37.48%

5-Day Price Return0.38%

EPS Normalized (Annual)$-1.88

ROA (5Y Avg)-232.75%

Net Profit Margin (Annual)-14755.38%

Month-to-Date Return31.50%

EBITD / Share (Annual)$-2.28

Operating Margin (Annual)-17921.54%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-480.73%

LT Debt / Equity (Quarterly)0.17x

EPS Basic Excl Extra (TTM)$-1.89

P/B Ratio (Annual)69.50x

Pretax Margin (TTM)-3527.08%

Book Value / Share (Annual)$0.07

Price vs S&P 500 (13W)36.58%

Beta7.52x

Revenue / Share (TTM)$0.01

ROE (TTM)-903.25%

52-Week Low$1.22

vGradeD

gGradeC

mGradeC

vgmGradeC

SER Earnings Surprise History

Q2 25-0.66est. -0.42

Q3 25-0.51est. -0.53

Q4 25-0.31est. -0.50

Q1 26-0.53est. -0.44

Q2 26-0.52est. -0.35

SER Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.00

4.17

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
SERSerina Therapeutics, Inc.	D	C	C	$2.70
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Serina Therapeutics, Inc.

Serina Therapeutics is a clinical-stage biotechnology company developing drug candidates for neurological diseases and pain management. The company's proprietary POZ Platform provides controlled drug loading and precise release mechanisms, offering advantages over traditional polymer-based delivery systems. Serina is focused on addressing limitations of existing technologies to enable treatment of challenging small-molecule drugs.